Literature DB >> 23504002

Impact of cytochrome P450 genes on suicide attempt and risk.

Eva M Peñas-Lledó1, M Eugenia G Naranjo, Adrián Llerena.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23504002     DOI： 10.1007/s00406-013-0402-7

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN： 0940-1334            Impact factor:   5.270


× No keyword cloud information.
  8 in total

1.  CYP2D6 and the severity of suicide attempts.

Authors:  Eva M Peñas-Lledó; Hilario Blasco-Fontecilla; Pedro Dorado; Concepción Vaquero-Lorenzo; Enrique Baca-García; Adrián Llerena
Journal:  Pharmacogenomics       Date:  2011-12-05       Impact factor: 2.533

2.  CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients.

Authors:  E M Peñas-Lledó; H D Trejo; P Dorado; A Ortega; H Jung; E Alonso; M E G Naranjo; M López-López; A Llerena
Journal:  Mol Psychiatry       Date:  2012-06-26       Impact factor: 15.992

3.  CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans.

Authors:  A Llerena; P Dorado; R Ramírez; I González; M Alvarez; E M Peñas-Lledó; B Pérez; L R Calzadilla
Journal:  Pharmacogenomics J       Date:  2010-12-07       Impact factor: 3.550

4.  High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases.

Authors:  A L Zackrisson; B Lindblom; J Ahlner
Journal:  Clin Pharmacol Ther       Date:  2009-11-11       Impact factor: 6.875

5.  CYP2D6 in the brain: impact on suicidality.

Authors:  J C Stingl; R Viviani
Journal:  Clin Pharmacol Ther       Date:  2011-01-19       Impact factor: 6.875

6.  High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders.

Authors:  E M Peñas-Lledó; P Dorado; Z Agüera; M Gratacós; X Estivill; F Fernández-Aranda; A Llerena
Journal:  Mol Psychiatry       Date:  2011-02-15       Impact factor: 15.992

7.  Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients.

Authors:  Alessandro Serretti; Raffaella Calati; Isabelle Massat; Sylvie Linotte; Siegfried Kasper; Yves Lecrubier; Roser Sens-Espel; Joseph Bollen; Joseph Zohar; Jacques Berlo; Patricia Lienard; Diana De Ronchi; Julien Mendlewicz; Daniel Souery
Journal:  Int Clin Psychopharmacol       Date:  2009-09       Impact factor: 1.659

8.  The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder.

Authors:  Peter Höfer; Alexandra Schosser; Raffaella Calati; Alessandro Serretti; Isabelle Massat; Neslihan Aygun Kocabas; Anastasios Konstantinidis; Sylvie Linotte; Julien Mendlewicz; Daniel Souery; Joseph Zohar; Alzbeta Juven-Wetzler; Stuart Montgomery; Siegfried Kasper
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-10-19       Impact factor: 5.270
  8 in total
  2 in total

Review 1.  CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.

Authors:  Eva M Peñas-Lledó; Adrián Llerena
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

2.  A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances.

Authors:  E Peñas-Lledó; S Guillaume; M E G Naranjo; A Delgado; I Jaussent; H Blasco-Fontecilla; P Courtet; A LLerena
Journal:  Pharmacogenomics J       Date:  2014-08-12       Impact factor: 3.550
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.